- Tarsus to Participate in Upcoming Investor Conferences
- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
- Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
- Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
- Tarsus to Participate at Upcoming Investor Conferences
- Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
- Tarsus Announces Pricing of $100.0 Million Public Offering
- Tarsus Announces Proposed $100.0 Million Public Offering
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
More ▼
Key statistics
On Monday, Tarsus Pharmaceuticals Inc (TARS:NSQ) closed at 27.14, 115.91% above the 52 week low of 12.57 set on Oct 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.25 |
---|---|
High | 27.92 |
Low | 26.42 |
Bid | 20.00 |
Offer | 30.90 |
Previous close | 27.14 |
Average volume | 583.89k |
---|---|
Shares outstanding | 37.78m |
Free float | 33.21m |
P/E (TTM) | -- |
Market cap | 1.04bn USD |
EPS (TTM) | -4.72 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼